Canexis Pharma has received extended approval from Swissmedic GMP manufacturing authorization (Part I) for the production of bulk finished medicinal products. This means that Canexis is now able to produce not only active ingredients such as cannabidiol (CBD) and dronabinol (THC), but also standardized drug bases for formulations in pharmacies and for the development of finished medicinal products – in compliance with the strictest pharmaceutical standards.
With this expansion, Canexis strengthens its position as vertically integrated full-service provider of pharmaceutical cannabis products. The modern production facility in Schlattingen (TG) enables the daily production of up to 100 kg of highly pure active ingredient. Parallel to the planned international export, the Swiss market will also be supplied with additional GMP-compliant products starting at the end of 2025.
You can read the full press release here: